← Back to search
DAY ZERO DIAGNOSTICS INC
WATERTOWN, MA, 02472
UnclaimedClaim this profile (free)
Subcontracting experience
5 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN ULTRA-HIGH ENRICHMENT SAMPLE PREPARATION PROCESS (BLOOD2BAC‎¢) THAT CAN EXTRACT BACTERIAL WHOLE GENOME SEQUENCES FROM PATIENT BLOOD SAMPLES EVEN WHEN THERE ARE JUST A HANDFUL OF BACTERIAL CELLS PRESENT IN THE SAMPLE. WE HAVE ALSO DEVELOPED A PROPRIETARY MACHINE LEARNING ALGORITHM (KEYNOME®) THAT CAN USE THE DNA SEQUENCES TO IDENTIFY A BACTERIAL PATHOGEN AND PREDICT ITS ANTIBIOTIC SUSCEPTIBILITY PROFILE. KEYNOME IS TRAINED ON A LARGE SCALE DATABASE (MICROHMDB®) THAT CONTAINS THE WHOLE GENOME SEQUENCES OF BACTERIAL PATHOGENS MATCHED TO THEIR KNOWN ANTIBIOTIC RESISTANCE PROFILE. OUR APPROACH ALLOWS FOR THE SIMULTANEOUS TESTING OF A VAST NUMBER OF BACTERIAL SPECIES AND KNOWN RESISTANCE MARKERS, ALONG WITH THE ABILITY TO IDENTIFY NOVEL RESISTANCE DETERMINANTS AS THEY EMERGE. WITH DAY ZERO DIAGNOSTICS, PHYSICIANS CAN TREAT PATIENTS WITH THE MOST EFFECTIVE DRUG IN HOURS, AVOIDING THE COMPLICATIONS, COSTS, AND FRUSTRATION ASSOCIATED WITH EMPIRIC THERAPY. 4500004389 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $1,499,992 | Feb 11, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN ULTRA-HIGH ENRICHMENT SAMPLE PREPARATION PROCESS (BLOOD2BAC‎¢) THAT CAN EXTRACT BACTERIAL WHOLE GENOME SEQUENCES FROM PATIENT BLOOD SAMPLES EVEN WHEN THERE ARE JUST A HANDFUL OF BACTERIAL CELLS PRESENT IN THE SAMPLE. WE HAVE ALSO DEVELOPED A PROPRIETARY MACHINE LEARNING ALGORITHM (KEYNOME®) THAT CAN USE THE DNA SEQUENCES TO IDENTIFY A BACTERIAL PATHOGEN AND PREDICT ITS ANTIBIOTIC SUSCEPTIBILITY PROFILE. KEYNOME IS TRAINED ON A LARGE SCALE DATABASE (MICROHMDB®) THAT CONTAINS THE WHOLE GENOME SEQUENCES OF BACTERIAL PATHOGENS MATCHED TO THEIR KNOWN ANTIBIOTIC RESISTANCE PROFILE. OUR APPROACH ALLOWS FOR THE SIMULTANEOUS TESTING OF A VAST NUMBER OF BACTERIAL SPECIES AND KNOWN RESISTANCE MARKERS, ALONG WITH THE ABILITY TO IDENTIFY NOVEL RESISTANCE DETERMINANTS AS THEY EMERGE. WITH DAY ZERO DIAGNOSTICS, PHYSICIANS CAN TREAT PATIENTS WITH THE MOST EFFECTIVE DRUG IN HOURS, AVOIDING THE COMPLICATIONS, COSTS, AND FRUSTRATION ASSOCIATED WITH EMPIRIC THERAPY. 4500004389 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $622,358 | Mar 27, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN ULTRA-HIGH ENRICHMENT SAMPLE PREPARATION PROCESS (BLOOD2BAC‎¢) THAT CAN EXTRACT BACTERIAL WHOLE GENOME SEQUENCES FROM PATIENT BLOOD SAMPLES EVEN WHEN THERE ARE JUST A HANDFUL OF BACTERIAL CELLS PRESENT IN THE SAMPLE. WE HAVE ALSO DEVELOPED A PROPRIETARY MACHINE LEARNING ALGORITHM (KEYNOME®) THAT CAN USE THE DNA SEQUENCES TO IDENTIFY A BACTERIAL PATHOGEN AND PREDICT ITS ANTIBIOTIC SUSCEPTIBILITY PROFILE. KEYNOME IS TRAINED ON A LARGE SCALE DATABASE (MICROHMDB®) THAT CONTAINS THE WHOLE GENOME SEQUENCES OF BACTERIAL PATHOGENS MATCHED TO THEIR KNOWN ANTIBIOTIC RESISTANCE PROFILE. OUR APPROACH ALLOWS FOR THE SIMULTANEOUS TESTING OF A VAST NUMBER OF BACTERIAL SPECIES AND KNOWN RESISTANCE MARKERS, ALONG WITH THE ABILITY TO IDENTIFY NOVEL RESISTANCE DETERMINANTS AS THEY EMERGE. WITH DAY ZERO DIAGNOSTICS, PHYSICIANS CAN TREAT PATIENTS WITH THE MOST EFFECTIVE DRUG IN HOURS, AVOIDING THE COMPLICATIONS, COSTS, AND FRUSTRATION ASSOCIATED WITH EMPIRIC THERAPY. 4500004389 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | -$50,000 | Nov 3, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN ULTRA-HIGH ENRICHMENT SAMPLE PREPARATION PROCESS (BLOOD2BAC‎¢) THAT CAN EXTRACT BACTERIAL WHOLE GENOME SEQUENCES FROM PATIENT BLOOD SAMPLES EVEN WHEN THERE ARE JUST A HANDFUL OF BACTERIAL CELLS PRESENT IN THE SAMPLE. WE HAVE ALSO DEVELOPED A PROPRIETARY MACHINE LEARNING ALGORITHM (KEYNOME®) THAT CAN USE THE DNA SEQUENCES TO IDENTIFY A BACTERIAL PATHOGEN AND PREDICT ITS ANTIBIOTIC SUSCEPTIBILITY PROFILE. KEYNOME IS TRAINED ON A LARGE SCALE DATABASE (MICROHMDB®) THAT CONTAINS THE WHOLE GENOME SEQUENCES OF BACTERIAL PATHOGENS MATCHED TO THEIR KNOWN ANTIBIOTIC RESISTANCE PROFILE. OUR APPROACH ALLOWS FOR THE SIMULTANEOUS TESTING OF A VAST NUMBER OF BACTERIAL SPECIES AND KNOWN RESISTANCE MARKERS, ALONG WITH THE ABILITY TO IDENTIFY NOVEL RESISTANCE DETERMINANTS AS THEY EMERGE. WITH DAY ZERO DIAGNOSTICS, PHYSICIANS CAN TREAT PATIENTS WITH THE MOST EFFECTIVE DRUG IN HOURS, AVOIDING THE COMPLICATIONS, COSTS, AND FRUSTRATION ASSOCIATED WITH EMPIRIC THERAPY. 4500004389 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | -$824,815 | Jul 27, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | DAY ZERO DIAGNOSTICS IS DEVELOPING A CULTURE-FREE, SEQUENCING-BASED DIAGNOSTIC THAT IDENTIFIES WITHIN HOURS BOTH THE SPECIES AND THE ANTIBIOTIC RESISTANCE PROFILE OF A BACTERIAL INFECTION. WE HAVE DEVELOPED AN ULTRA-HIGH ENRICHMENT SAMPLE PREPARATION PROCESS (BLOOD2BAC‎¢) THAT CAN EXTRACT BACTERIAL WHOLE GENOME SEQUENCES FROM PATIENT BLOOD SAMPLES EVEN WHEN THERE ARE JUST A HANDFUL OF BACTERIAL CELLS PRESENT IN THE SAMPLE. WE HAVE ALSO DEVELOPED A PROPRIETARY MACHINE LEARNING ALGORITHM (KEYNOME®) THAT CAN USE THE DNA SEQUENCES TO IDENTIFY A BACTERIAL PATHOGEN AND PREDICT ITS ANTIBIOTIC SUSCEPTIBILITY PROFILE. KEYNOME IS TRAINED ON A LARGE SCALE DATABASE (MICROHMDB®) THAT CONTAINS THE WHOLE GENOME SEQUENCES OF BACTERIAL PATHOGENS MATCHED TO THEIR KNOWN ANTIBIOTIC RESISTANCE PROFILE. OUR APPROACH ALLOWS FOR THE SIMULTANEOUS TESTING OF A VAST NUMBER OF BACTERIAL SPECIES AND KNOWN RESISTANCE MARKERS, ALONG WITH THE ABILITY TO IDENTIFY NOVEL RESISTANCE DETERMINANTS AS THEY EMERGE. WITH DAY ZERO DIAGNOSTICS, PHYSICIANS CAN TREAT PATIENTS WITH THE MOST EFFECTIVE DRUG IN HOURS, AVOIDING THE COMPLICATIONS, COSTS, AND FRUSTRATION ASSOCIATED WITH EMPIRIC THERAPY. 4500004389 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $7,835,738 | Oct 20, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.